James P Zacny1, Sandra Gutierrez. 1. Department of Anesthesia and Critical Care, University of Chicago, Chicago, Illinois 60637, USA. jzacny@dacc.uchicago.edu
Abstract
OBJECTIVES: To compare within the same individuals two typically prescribed doses of hydrocodone/acetaminophen and oxycodone/acetaminophen products for their subjective, psychomotor, and physiological effects in healthy volunteers. DESIGN: A randomized, placebo-controlled, double-blind, crossover, six-session clinical laboratory study, enrolling 16 healthy participants (27.2 +/- 4.4 years of age). Participants received 5 mg hydrocodone/325 mg acetaminophen, 10 mg hydrocodone/650 mg acetaminophen, 5 mg oxycodone/325 mg acetaminophen, 10 mg oxycodone/650 mg acetaminophen, 650 mg acetaminophen, and placebo in different sessions. RESULTS:Oxycodone/acetaminophen and hydrocodone/acetaminophen at the 5-mg opioid dose produced few subjective effects and no significant psychomotor impairment. Relative to placebo, the 10-mg oxycodone combination produced a wider spectrum of subjective effects that were statistically significant than did the 10-mg hydrocodone combination. The 10-mg oxycodone combination also produced a greater degree of miosis than the 10-mg hydrocodone combination. Both drug combinations impaired psychomotor performance at the 10-mg opioid dose. CONCLUSIONS: The results of this study, albeit in pain-free individuals, may inform physicians who prescribe, and pharmacists who dispense, two widely prescribed opioid/acetaminophen combination products on how patients might be feeling from the drugs. Patients prescribed either of the two opioid/acetaminophen combination products may experience a number of subjective effects, including effects that would contraindicate certain activities, and they should be cautioned accordingly. However, this study documented rather large differences in magnitude of subjective effects between 10 mg oxycodone/650 mg acetaminophen and placebo, and physicians and pharmacists, and ultimately patients, should be aware of these differences.
RCT Entities:
OBJECTIVES: To compare within the same individuals two typically prescribed doses of hydrocodone/acetaminophen and oxycodone/acetaminophen products for their subjective, psychomotor, and physiological effects in healthy volunteers. DESIGN: A randomized, placebo-controlled, double-blind, crossover, six-session clinical laboratory study, enrolling 16 healthy participants (27.2 +/- 4.4 years of age). Participants received 5 mg hydrocodone/325 mg acetaminophen, 10 mg hydrocodone/650 mg acetaminophen, 5 mg oxycodone/325 mg acetaminophen, 10 mg oxycodone/650 mg acetaminophen, 650 mg acetaminophen, and placebo in different sessions. RESULTS:Oxycodone/acetaminophen and hydrocodone/acetaminophen at the 5-mg opioid dose produced few subjective effects and no significant psychomotor impairment. Relative to placebo, the 10-mg oxycodone combination produced a wider spectrum of subjective effects that were statistically significant than did the 10-mg hydrocodone combination. The 10-mg oxycodone combination also produced a greater degree of miosis than the 10-mg hydrocodone combination. Both drug combinations impaired psychomotor performance at the 10-mg opioid dose. CONCLUSIONS: The results of this study, albeit in pain-free individuals, may inform physicians who prescribe, and pharmacists who dispense, two widely prescribed opioid/acetaminophen combination products on how patients might be feeling from the drugs. Patients prescribed either of the two opioid/acetaminophen combination products may experience a number of subjective effects, including effects that would contraindicate certain activities, and they should be cautioned accordingly. However, this study documented rather large differences in magnitude of subjective effects between 10 mg oxycodone/650 mg acetaminophen and placebo, and physicians and pharmacists, and ultimately patients, should be aware of these differences.
Authors: Ajay D Wasan; Edgar L Ross; Edward Michna; Lori Chibnik; Shelly F Greenfield; Roger D Weiss; Robert N Jamison Journal: J Pain Date: 2012-01-14 Impact factor: 5.820
Authors: Benjamin W Friedman; Lorena Abril Ochoa; Farnia Naeem; Hector R Perez; Joanna L Starrels; Eddie Irizarry; Andrew Chertoff; Polly E Bijur; E John Gallagher Journal: Ann Emerg Med Date: 2019-11-01 Impact factor: 5.721
Authors: William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh Journal: Psychopharmacology (Berl) Date: 2010-07-28 Impact factor: 4.530
Authors: Mohammed A Issa; Sanjeet Narang; Robert N Jamison; Edward Michna; Robert R Edwards; David M Penetar; Ajay D Wasan Journal: Clin J Pain Date: 2014-06 Impact factor: 3.442
Authors: Jeffrey F Scherrer; Joanne Salas; Kathleen K Bucholz; F David Schneider; Thomas Burroughs; Laurel A Copeland; Mark D Sullivan; Patrick J Lustman Journal: Pharmacoepidemiol Drug Saf Date: 2016-03-22 Impact factor: 2.890
Authors: Pernille Ravn; Erik L Secher; Ulrik Skram; Trine Therkildsen; Lona L Christrup; Mads U Werner Journal: J Pain Res Date: 2013-01-09 Impact factor: 3.133
Authors: Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill Journal: Cell Mol Neurobiol Date: 2020-11-27 Impact factor: 4.231